Skandinaviska Enskilda Banken AB publ Has $4.80 Million Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Key Points

• Skandinaviska Enskilda Banken AB publ reduced its holdings in Janux Therapeutics by 13.3%, selling 27,347 shares and now holding 177,820 shares worth approximately $4.8 million.
• Institutional investors currently own 75.39% of Janux Therapeutics, with notable increases in holdings by firms such as GAMMA Investing LLC, which lifted its stake by 1,574.0% during the first quarter.
• Janux's stock performance shows a market cap of $1.54 billion with a 52-week range between $22.48 and $71.71, and analysts have an average price target of $91.89.

Skandinaviska Enskilda Banken AB publ lowered its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 13.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 177,820 shares of the company's stock after selling 27,347 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned approximately 0.30% of Janux Therapeutics worth $4,801,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in shares of Janux Therapeutics by 1,574.0% during the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after acquiring an additional 1,574 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after acquiring an additional 442 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Janux Therapeutics during the 4th quarter worth about $59,000. FNY Investment Advisers LLC boosted its stake in shares of Janux Therapeutics by 6,928.6% during the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after acquiring an additional 2,425 shares in the last quarter. Finally, KBC Group NV bought a new stake in shares of Janux Therapeutics during the 1st quarter worth about $66,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Stock Up 0.0%

Janux Therapeutics stock traded up $0.00 during trading hours on Thursday, hitting $24.23. The stock had a trading volume of 232,934 shares, compared to its average volume of 940,666. The company has a 50-day moving average of $24.79 and a two-hundred day moving average of $29.96. The company has a market cap of $1.43 billion, a PE ratio of -17.84 and a beta of 2.86. Janux Therapeutics, Inc. has a fifty-two week low of $22.48 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.05. As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Raymond James Financial started coverage on Janux Therapeutics in a research note on Friday, July 11th. They set an "outperform" rating and a $65.00 price target for the company. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $91.89.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.